48 Validation of a Multi-omic Biosignature to Predict Locoregional Recurrence Risk and the Benefit of Adjuvant Radiation Therapy in Women With Early-Stage Invasive Breast Cancer Treated With Breast-Conserving Surgery and Endocrine Therapy
ByG. Bruce Mann,Karuna Mittal,Richard De Boer,Caroline MacCallum,Michael D. Alvarado,Michael Christie,Frank Vicini, MD,Chirag Shah, MD,Y. V. Zou,Mark Mentrikoski,Jess Savala,David J. Dabbs,Steven C. Shivers,Pat W. Whitworth,Troy Bremer In an external blinded validation of 426 women with HR-positive, HER2-negative IBC at Royal Melbourne Hospital, a multi-omic test stratified patients by LRR risk and RT benefit, identifying subgroups who could safely omit RT and those with elevated risk who benefited significantly.
